Dr. Eric Yu is a Partner of Matrix China. He joined Matrix China in 2014. Dr. Yu‘s investment cases at Matrix China include: Peijia , RemeGen, Chemclin, InventisBio, Biostar, Genecast, Ambrx, Advaccine, Scivita Medcial, etc.

Prior to joining Matrix China, Dr. Yu was responsible for healthcare investments at Fidelity Growth Partners China from 2012 to 2014. From 2009 to 2012, Dr. Yu served as the Deputy General Manager of the Northeast Office of Shenzhen Capital Group, where he helped found the branch and was responsible for developing investment opportunities in the region. Prior to this, Dr. Yu worked in the Global Healthcare Department of UBS Investment Bank and McKinsey’s New York office. Dr. Yu has also conducted research in bioinformatics and structured drug design at Yale University and Columbia University, respectively.

In 2021, Dr. Yu was rated by 36Kr as China’s TOP20 Investors in Healthcare.